FR104, an antagonist anti-CD28 monovalent fab' antibody, prevents alloimmunization and allows calcineurin inhibitor minimization in nonhuman primate renal allograft

American Journal of Transplantation

Volumn 15, Issue 1, 2015, Pages 88-100

  Poirier, N ^a,b,c   Dilek, N ^a,b,c   Mary, C ^a,b,c   Ville, S ^a,b   Coulon, F ^a,b   Branchereau, J ^a,b,d   Tillou, X ^a,b,e   Charpy, V ^a,b   Pengam, S ^a,b   Nerriere Daguin, V ^a,b   Hervouet, J ^a,b   Minault, D ^a,b   Le Bas Bernardet, S ^a,b,d   Renaudin, K ^d   Vanhove, B ^a,b,c   Blancho, G ^a,b,d  

^a INSERM   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c Effimune SAS   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

^e CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; CALCINEURIN INHIBITOR; CORTICOSTEROID; FR104; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE SODIUM SUCCINATE; MONOCLONAL ANTIBODY CD28; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG; CD28 ANTIGEN; MESSENGER RNA;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ALLOIMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DELAYED GRAFT FUNCTION; DNA DETERMINATION; DNA METHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG WITHDRAWAL; ELIMINATION HALF-LIFE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHUMAN; PAPIO ANUBIS; PRIMATE MODEL; REGULATORY T LYMPHOCYTE; SINGLE DRUG DOSE; TREATMENT RESPONSE; ALLOTRANSPLANTATION; ANIMAL; BABOON; CELL CULTURE; DRUG EFFECTS; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENETICS; GRAFT REJECTION; IMMUNIZATION; IMMUNOLOGY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD28; BLOTTING, WESTERN; CALCINEURIN INHIBITORS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNIZATION; IMMUNOENZYME TECHNIQUES; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOSUPPRESSION; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; PAPIO; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84919622359     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12964     Document Type: Article

References (65)

1. Berber I, Aydin C, Yigit B, et al. Blood pressure and graft outcome in renal transplantation. Transplant Proc 2005; 37: 997-998.
2. Nankivell BJ, Borrows RJ, Fung CL-S, O'Connell PJ, Allen RDM, Chapman JR., The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333.
3. Porrini E, Delgado P, Bigo C, et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006; 48: 134-142.
4. Poirier N, Blancho G, Vanhove B., A more selective costimulatory blockade of the CD28-B7 pathway. Transpl Int 2011; 24: 2-11.
5. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349: 1907-1915.
6. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
7. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
8. Vincenti F, Larsen CP, Alberu J, et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210-217.
9. Durrbach A, Pestana JM, Pearson T, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study). Am J Transplant 2010; 10: 547-557.
10. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91: 976-983.
11. Poirier N, Blancho G, Vanhove B., Alternatives to calcineurin inhibition in renal transplantation: Belatacept, the first co-stimulation blocker. Immunotherapy 2010; 2: 625-636.
12. Poirier N, Azimzadeh AM, Zhang T, et al. Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T-cells in organ transplantation. Sci Transl Med 2010; 2: 17ra10.
13. Poirier N, Mary C, Dilek N, et al. Preclinical efficacy and immunological safety of FR104, an antagonist anti-CD28 monovalent Fab' antibody. Am J Transplant 2012; 12: 2630-2640.
14. Poirier N, Blancho G, Vanhove B., CD28-specific immunomodulating antibodies: What can be learned from experimental models ? Am J Transplant 2012; 12: 1682-1690.
15. Zhang T, Fresnay S, Welty E, et al. Selective CD28 blockade attenuates acute and chronic rejection of murine cardiac allografts in a CTLA-4-dependent manner. Am J Transplant 2011; 11: 1599-1609.
16. Vanhove B, Laflamme G, Coulon F, et al. Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood 2003; 102: 564-570.
17. Haspot F, Villemain F, Laflamme G, et al. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002; 99: 2228-2234.
18. Li J, Semple K, Suh W-K, et al. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. Biol Blood Marrow Transplant 2011; 17: 962-969.
19. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ., Programmed death-1 ligand 1 interacts specifically with the B 7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27: 111-122.
20. Butte MJ, Peña-Cruz V, Kim M-J, Freeman GJ, Sharpe AH., Interaction of human PD-L1 and B7-1. Mol Immunol 2008; 45: 3567-3572.
21. Yao S, Zhu Y, Zhu G, et al. B7-h2 is a costimulatory ligand for CD28 in human. Immunity 2011; 34: 729-740.
22. Perrin PJ, June CH, Maldonado JH, Ratts RB, Racke MK., Blockade of CD28 during in vitro activation of encephalitogenic T cells or after disease onset ameliorates experimental autoimmune encephalomyelitis. J Immunol 1999; 163: 1704-1710.
23. Raychaudhuri SP, Kundu-Raychaudhuri S, Tamura K, et al. FR255734, a humanized, Fc-Silent, Anti-CD28 antibody, improves psoriasis in the SCID mouse-psoriasis xenograft model. J Invest Dermatol 2008; 128: 1969-1976.
24. Yu X-Z, Albert MH, Martin PJ, Anasetti C., CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest 2004; 113: 1624-1630.
25. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C., CD28-specific antibody prevents graft-versus-host disease in mice. J Immunol 2000; 164: 4564-4568.
26. Laskowski IA, Pratschke J, Wilhelm MJ, et al. Anti-CD28 monoclonal antibody therapy prevents chronic rejection of renal allografts in rats. J Am Soc Nephrol 2002; 13: 519-527.
27. Dong VM, Yuan X, Coito AJ, Waaga AM, Sayegh MH, Chandraker A., Mechanisms of targeting CD28 by a signaling monoclonal antibody in acute and chronic allograft rejection. Transplantation 2002; 73: 1310-1317.
28. Guillonneau C, Séveno C, Dugast A-S, et al. Anti-CD28 antibodies modify regulatory mechanisms and reinforce tolerance in CD40Ig-treated heart allograft recipients. J Immunol 2007; 179: 8164-8171.
29. Urakami H, Ostanin DV, Hünig T, Grisham MB., Combination of donor-specific blood transfusion with anti-CD28 antibody synergizes to prolong graft survival in rat liver transplantation. Transplant Proc 2006; 38: 3244-3246.
30. Dengler TJ, Szabo G, Sido B, et al. Prolonged allograft survival but no tolerance induction by modulating CD28 antibody JJ319 after high-responder rat heart transplantation. Transplantation 1999; 67: 392-398.
31. Haspot F, Séveno C, Dugast A-S, et al. Anti-CD28 antibody-induced kidney allograft tolerance related to tryptophan degradation and TCR class II B7 regulatory cells. Am J Transplant 2005; 5: 2339-2348.
32. Dugast A-S, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898-7906.
33. Dilek N, Poirier N, Usal C, Martinet B, Blancho G, Vanhove B., Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol 2012; 188: 4209-4216.
34. Mary C, Coulon F, Poirier N, et al. Antagonist properties of monoclonal antibodies targeting human CD28: Role of valency and the heavy-chain constant domain. MAbs 2013; 5: 47-55.
35. Tillou X, Poirier N, Le Bas-Bernardet S, et al. Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons. Kidney Int 2010; 78: 152-159.
36. Wieczorek G, Asemissen A, Model F, et al. Quantitative DNA methylation analysis of FOXP3 as a new method for counting regulatory T cells in peripheral blood and solid tissue. Cancer Res 2009; 69: 599-608.
37. Poirier N, Maillet F, Barussaud M-L, et al. Acute humoral rejection of renal transplants in alloimmunized pigs. J Surg Res 2007; 139: 261-268.
38. Poirier N, Blancho G., Recombinant human c1-inhibitor inhibits cytotoxicity induced by allo- and xenoantibodies. Transplant Proc 2008; 40: 581-583.
39. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
40. Curotto de Lafaille MA, Lafaille JJ., Natural and adaptive foxp3+ regulatory T cells: More of the same or a division of labor ? Immunity 2009; 30: 626-635.
41. Chauhan SK, Saban DR, Lee HK, Dana R., Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation. J Immunol 2009; 182: 148-153.
42. Himmel ME, MacDonald KG, Garcia RV, Steiner TS, Levings MK., Helios+ and Helios- cells coexist within the natural FOXP3+ T regulatory cell subset in humans. J Immunol 2013; 190: 2001-2008.
43. Dilek N, Poirier N, Hulin P, et al. Targeting CD28, CTLA-4,PD-L1 costimulation differentially controls immune synapses, function of human regulatory, conventional T-cells. PLoS ONE 2013; 8: e83139.
44. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355: 1018-1028.
45. Poirier N, Mary C, Le Bas-Bernardet S, et al. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28. MAbs 2014; 6: 697-707.
46. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the symphony study: Observational results 3 years after transplantation. Am J Transplant 2009; 9: 1876-1885.
47. Hernández D, Miquel R, Porrini E, et al. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007; 84: 706-714.
48. Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90: 68-74.
49. Gloor J, Cosio F, Lager DJ, Stegall MD., The spectrum of antibody-mediated renal allograft injury: Implications for treatment. Am J Transplant 2008; 8: 1367-1373.
50. Linterman MA, Vinuesa CG., Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol 2010; 32: 183-196.
51. Kim EJ, Kwun J, Gibby AC, et al. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. Am J Transplant 2014; 14: 59-69.
52. Fong L, Kwek SS, O'Brien S, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69: 609-615.
53. Yuan J, Gnjatic S, Li H, et al. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc Natl Acad Sci USA 2008; 105: 20410-20415.
54. Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008; 322: 271-275.
55. Thornton AM, Korty PE, Tran DQ, et al. Expression of Helios, an Ikaros transcription factor family member, differentiates thymic-derived from peripherally induced Foxp3+ T regulatory cells. J Immunol 2010; 184: 3433-3441.
56. Shevach EM, Thornton AM., tTregs, pTregs, and iTregs: Similarities and differences. Immunol Rev 2014; 259: 88-102.
57. Salomon B, Lenschow DJ, Rhee L, et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+ CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440.
58. Chen Y, Shen S, Gorentla BK, Gao J, Zhong X-P., Murine regulatory T cells contain hyperproliferative and death-prone subsets with differential ICOS expression. J Immunol 2012; 188: 1698-1707.
59. Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig MC, von Boehmer H., Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6: 1219-1227.
60. Belghith M, Bluestone JA, Barriot S, Mégret J, Bach J-F, Chatenoud L., TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003; 9: 1202-1208.
61. Fu S, Zhang N, Yopp AC, et al. TGF-beta induces Foxp3+ T-regulatory cells from CD4+ CD25- precursors. Am J Transplant 2004; 4: 1614-1627.
62. Benson MJ, Pino-Lagos K, Rosemblatt M, Noelle RJ., All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204: 1765-1774.
63. Li R, Perez N, Karumuthil-Melethil S, Prabhakar BS, Holterman MJ, Vasu C., Enhanced engagement of CTLA-4 induces antigen-specific CD4+ CD25+ Foxp3+ and CD4+ CD25- TGF-beta 1+ adaptive regulatory T cells. J Immunol 2007; 179: 5191-5203.
64. Chavez H, Beaudreuil S, Abbed K, et al. Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. Transpl Immunol 2007; 17: 243-248.
65. Bluestone JA, Liu W, Yabu JM, et al. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086-2096.